Adverum Biotechnologies Inc logo

ADVM - Adverum Biotechnologies Inc News Story

$10.81 0.3  3.0%

Last Trade - 25/09/20

Sector
Healthcare
Size
Mid Cap
Market Cap £806.9m
Enterprise Value £587.1m
Revenue £196k
Position in Universe 2322nd / 6417

BRIEF-Adverum Biotech Reports Positive Interim Data From Cohorts 1-3 Of Optic Phase 1 Trial Of Advm-022 Intravitreal Gene Therapy For Wet AMD

Mon 4th May, 2020 11:20pm
May 4 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES REPORTS POSITIVE INTERIM DATA FROM
COHORTS 1-3 OF OPTIC PHASE 1 TRIAL OF ADVM-022 INTRAVITREAL GENE
THERAPY FOR WET AMD
    * ADVERUM BIOTECHNOLOGIES INC - ROBUST EFFICACY AND EVIDENCE
OF A
DOSE RESPONSE FROM SINGLE INTRAVITREAL INJECTION (IVT) OF
ADVM-022
    * ADVERUM BIOTECHNOLOGIES INC - LONG-TERM DURABILITY BEYOND
1 YEAR
FROM SINGLE IVT INJECTION OF ADVM-022 WITH ZERO RESCUE
INJECTIONS IN COHORT 1
    * ADVERUM BIOTECHNOLOGIES INC - ENCOURAGING EARLY DATA FROM
COHORT
3
    * ADVERUM BIOTECHNOLOGIES INC - PLANS TO INITIATE A PLANNED
PHASE
1/2 CLINICAL TRIAL OF ADVM-022 FOR TREATMENT OF DIABETIC
RETINOPATHY IN H2

Source text for Eikon:  ID:nGNXc6kr69 
Further company coverage:  ADVM.O 

 (Reuters.Briefs@thomsonreuters.com)
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.